BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68:803-38. [PMID: 18416587 DOI: 10.2165/00003495-200868060-00006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Cachia J, Torpiano P, Pace D. Meropenem-induced thrombocytopenia: a paediatric case. BMJ Case Rep 2021;14:e243443. [PMID: 34479885 DOI: 10.1136/bcr-2021-243443] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Martens-lobenhoffer J, Bode-böger SM. Quantification of meropenem in human plasma by HILIC – tandem mass spectrometry. Journal of Chromatography B 2017;1046:13-7. [DOI: 10.1016/j.jchromb.2017.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, Kumeria T, Falconer JR. Oral meropenem for superbugs: challenges and opportunities. Drug Discov Today 2021;26:551-60. [PMID: 33197621 DOI: 10.1016/j.drudis.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tanaka S, Matsui H, Kasai M, Kunishiro K, Kakeya N, Shirahase H. Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics. J Antibiot 2011;64:233-42. [DOI: 10.1038/ja.2010.164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Akhi MT, Asghari B, Nahaei MR, Memar MY, Lari AR, Naghili B, Pirzadeh T. Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients. GMS Hyg Infect Control 2014;9:Doc12. [PMID: 25152857 DOI: 10.3205/dgkh000232] [Reference Citation Analysis]
6 Martens-lobenhoffer J, Monastyrski D, Tröger U, Bode-böger SM. Stability of meropenem in plasma versus dried blood spots (DBS). Journal of Pharmaceutical and Biomedical Analysis 2019;170:279-84. [DOI: 10.1016/j.jpba.2019.03.055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Wong G, Farkas A, Sussman R, Daroczi G, Hope WW, Lipman J, Roberts JA. Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother 2015;59:1411-7. [PMID: 25512414 DOI: 10.1128/AAC.04001-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Yayan J, Ghebremedhin B, Rasche K. Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study. BMC Pharmacol Toxicol 2016;17:10. [PMID: 27004519 DOI: 10.1186/s40360-016-0056-y] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Muro T, Sasaki T, Hosaka N, Umeda Y, Takemoto S, Yamamoto H, Kamimura H, Higuchi S, Karube Y. Population pharmacokinetic analysis of meropenem in Japanese adult patients. J Clin Pharm Ther 2011;36:230-6. [PMID: 21366653 DOI: 10.1111/j.1365-2710.2010.01171.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kaska M, Havel E, Selke-Krulichova I, Safranek P, Bezouska J, Martinkova J. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:219-26. [PMID: 29582860 DOI: 10.5507/bp.2018.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Nunez-Nunez M, Murillo-Izquierdo M, Moya-Martin M, Hoxha M, Quesada Pérez MT, Oltra-Hostalet F, Alonso-Ramos H, Cordero-Ramos J, Barrera-Cabeza J, Retamar-Gentil P, Fernández-Del-Castillo SS. Compatibility of prolonged infusion antibiotics during Y-site administration. Nurs Crit Care 2022. [PMID: 35088491 DOI: 10.1111/nicc.12754] [Reference Citation Analysis]
12 Kong L, Tang Y, Zhang X, Lu G, Yu M, Shi Q, Wu X. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation. Ann Pharmacother 2017;51:970-5. [PMID: 28677407 DOI: 10.1177/1060028017719715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Schneider F, Gessner A, El-najjar N. Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update. Antibiotics 2022;11:173. [DOI: 10.3390/antibiotics11020173] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16:R113. [PMID: 22742765 DOI: 10.1186/cc11405] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
15 Troisi L, Granito C, Pindinelli E. Novel and Recent Synthesis and Applications of β-Lactams. In: Banik BK, editor. Heterocyclic Scaffolds I. Berlin: Springer Berlin Heidelberg; 2010. pp. 101-209. [DOI: 10.1007/7081_2009_12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
16 Jamieson C, Allwood MC, Stonkute D, Wallace A, Wilkinson AS, Hills T; BSAC Drug Stability Working Party. Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting. Eur J Hosp Pharm 2020;27:e53-7. [PMID: 32296506 DOI: 10.1136/ejhpharm-2018-001699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Marcoleta AE, Arros P, Varas MA, Costa J, Rojas-Salgado J, Berríos-Pastén C, Tapia-Fuentes S, Silva D, Fierro J, Canales N, Chávez FP, Gaete A, González M, Allende ML, Lagos R. The highly diverse Antarctic Peninsula soil microbiota as a source of novel resistance genes. Sci Total Environ 2021;810:152003. [PMID: 34856283 DOI: 10.1016/j.scitotenv.2021.152003] [Reference Citation Analysis]
18 Charvet A, Garcin F, Albanèse J, Martin C. Méningites nosocomiales. Antibiotiques 2009;11:18-28. [DOI: 10.1016/j.antib.2008.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Weinelt FA, Stegemann MS, Theloe A, Pfäfflin F, Achterberg S, Weber F, Dübel L, Mikolajewska A, Uhrig A, Kiessling P, Huisinga W, Michelet R, Hennig S, Kloft C. Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics 2022;11:758. [DOI: 10.3390/antibiotics11060758] [Reference Citation Analysis]
20 Sjövall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA. Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother 2018;73:191-8. [PMID: 28961812 DOI: 10.1093/jac/dkx330] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
21 Ng SMS, Sioson JSP, Yap JM, Ng FM, Ching HSV, Teo JWP, Jureen R, Hill J, Chia CSB. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. Eur J Clin Microbiol Infect Dis 2018;37:141-8. [DOI: 10.1007/s10096-017-3114-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
22 Oelschlaeger P, Ai N, Duprez KT, Welsh WJ, Toney JH. Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem 2010;53:3013-27. [PMID: 20121112 DOI: 10.1021/jm9012938] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
23 Hain G, Goldbart A, Sagi O, Ben-Shimol S. High Rates of Antibiotic Nonsusceptibility in Gram-negative Urinary Tract Infection in Children With Risk Factors Occurring in the Preceding Month: Considerations for Choosing Empiric Treatment. Pediatr Infect Dis J 2021;40:639-44. [PMID: 33872277 DOI: 10.1097/INF.0000000000003147] [Reference Citation Analysis]
24 Liebchen U, Salletmeier H, Kallee S, Scharf C, Huebner L, Weber A, Zoller M. Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study. Sci Rep 2021;11:17211. [PMID: 34446780 DOI: 10.1038/s41598-021-96744-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ahmadi A, Vogler B, Deng Y, Wu T. Removal of meropenem from environmental matrices by electrochemical oxidation using Co/Bi/TiO 2 nanotube electrodes. Environ Sci : Water Res Technol 2020;6:2197-208. [DOI: 10.1039/d0ew00184h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Sahulka SQ, Bhattarai B, Bhattacharjee AS, Tanner W, Mahar RB, Goel R. Differences in chlorine and peracetic acid disinfection kinetics of Enterococcus faecalis and Escherichia fergusonii and their susceptible strains based on gene expressions and genomics. Water Res 2021;203:117480. [PMID: 34392043 DOI: 10.1016/j.watres.2021.117480] [Reference Citation Analysis]
27 Wilson APR. Sparing carbapenem usage. J Antimicrob Chemother 2017;72:2410-7. [PMID: 28637307 DOI: 10.1093/jac/dkx181] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
28 Testero SA, Fisher JF, Mobashery S. β‐Lactam Antibiotics. Burger's Medicinal Chemistry and Drug Discovery. Wiley; 2003. pp. 257-402. [DOI: 10.1002/0471266949.bmc226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Frei A, Amado M, Cooper MA, Blaskovich MAT. Light-Activated Rhenium Complexes with Dual Mode of Action against Bacteria. Chemistry 2020;26:2852-8. [PMID: 31788867 DOI: 10.1002/chem.201904689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
30 Samarinas M, Dimitropoulos K, Zachos I, Gravas S, Karatzas A, Tzortzis V. A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance. World J Urol 2016;34:1555-9. [PMID: 26951136 DOI: 10.1007/s00345-016-1800-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wu G, Cheon E. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis. Expert Opinion on Pharmacotherapy 2018;19:1495-502. [DOI: 10.1080/14656566.2018.1512586] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Shoulders BR, Casapao AM, Venugopalan V. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clinical Therapeutics 2020;42:692-702. [DOI: 10.1016/j.clinthera.2020.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Ordóñez Mejia JL, Roberts MS, Lipman J, Roberts JA. Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. Antimicrob Agents Chemother 2016;60:4577-84. [PMID: 27185798 DOI: 10.1128/AAC.00531-16] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
34 Ben Jaballah M, Ambily Rajendran A, Prieto-Simón B, Dridi C. Development of a sustainable nanosensor using green Cu nanoparticles for simultaneous determination of antibiotics in drinking water. Anal Methods 2022. [PMID: 35545944 DOI: 10.1039/d2ay00419d] [Reference Citation Analysis]
35 Hu YY, Cai JC, Zhou HW, Zhang R, Chen GX. Rapid detection of porins by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Front Microbiol 2015;6:784. [PMID: 26300858 DOI: 10.3389/fmicb.2015.00784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
36 Chen LR, Zhou HW, Cai JC, Zhang R, Chen GX. Detection of plasmid-mediated IMP-1 metallo-beta-lactamase and quinolone resistance determinants in an ertapenem-resistant Enterobacter cloacae isolate. J Zhejiang Univ Sci B 2009;10:348-54. [PMID: 19434761 DOI: 10.1631/jzus.B0820302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
37 Choi SH, Ahn MY, Chung JW, Lee MK. In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center. Infect Chemother 2015;47:175-80. [PMID: 26483991 DOI: 10.3947/ic.2015.47.3.175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Roth T, Fiedler S, Mihai S, Parsch H. Determination of meropenem levels in human serum by high-performance liquid chromatography with ultraviolet detection: Determination of meropenem in human serum. Biomed Chromatogr 2017;31:e3880. [DOI: 10.1002/bmc.3880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
39 Taha M. Infections à méningocoques. EMC - Maladies infectieuses 2012;9:1-17. [DOI: 10.1016/s1166-8598(12)58119-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Singh AK, Bhunia AK. Animal-Use Antibiotics Induce Cross-Resistance in Bacterial Pathogens to Human Therapeutic Antibiotics. Curr Microbiol 2019;76:1112-7. [PMID: 31346691 DOI: 10.1007/s00284-019-01744-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yayan J, Ghebremedhin B, Rasche K. No Development of Imipenem Resistance in Pneumonia Caused by Escherichia coli. Medicine (Baltimore) 2015;94:e1020. [PMID: 26107669 DOI: 10.1097/MD.0000000000001020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Lima-Rogel V, Olguín-Mexquitic L, Kühn-Córdova I, Correa-López T, Romano-Aguilar M, Romero-Méndez MDC, Medellín-Garibay SE, Romano-Moreno S. Optimizing Meropenem Therapy for Severe Nosocomial Infections in Neonates. J Pharm Sci 2021:S0022-3549(21)00284-7. [PMID: 34089712 DOI: 10.1016/j.xphs.2021.05.019] [Reference Citation Analysis]
43 Lan J, Wu Z, Wang X, Wang Y, Yao F, Zhao B, Wang Y, Chen J, Chen C. Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sethi SK, Krishnappa V, Nangethu N, Nemer P, Frazee LA, Raina R. Antibiotic Dosing in Sustained Low-Efficiency Dialysis in Critically Ill Patients. Can J Kidney Health Dis 2018;5:2054358118792229. [PMID: 30116545 DOI: 10.1177/2054358118792229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
45 Cross T, Ransegnola B, Shin JH, Weaver A, Fauntleroy K, VanNieuwenhze MS, Westblade LF, Dörr T. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother 2019;63:e00756-19. [PMID: 31285232 DOI: 10.1128/AAC.00756-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
46 Ordóñez K, Feinstein MM, Reyes S, Hernández-Gómez C, Pallares C, Villegas MV. Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia. Braz J Infect Dis 2019;23:237-45. [PMID: 31344357 DOI: 10.1016/j.bjid.2019.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
47 Terbtothakun P, Nwabor OF, Siriyong T, Voravuthikunchai SP, Chusri S. Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Escherichia coli Harboring blaNDM-1 and blaNDM-5. Antibiotics (Basel) 2021;10:1023. [PMID: 34439073 DOI: 10.3390/antibiotics10081023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 England K, Boshoff HI, Arora K, Weiner D, Dayao E, Schimel D, Via LE, Barry CE 3rd. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012;56:3384-7. [PMID: 22450968 DOI: 10.1128/AAC.05690-11] [Cited by in Crossref: 72] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
49 Fritsche TR, Sader HS, Stillwell MG, Jones RN. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003–2007). Diagnostic Microbiology and Infectious Disease 2009;63:440-6. [DOI: 10.1016/j.diagmicrobio.2009.01.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Dhaese SAM, De Kezel M, Callant M, Boelens J, De Bus L, Depuydt P, De Waele JJ. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study. J Crit Care 2018;47:164-8. [PMID: 30005302 DOI: 10.1016/j.jcrc.2018.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kobayashi R, Suzuki D, Sano H, Kishimoto K, Yasuda K, Kobayashi K. Effect of meropenem with or without immunoglobulin as second-line therapy for pediatric febrile neutropenia: MEPM ± IVIG for pediatric FN. Pediatr Int 2014;56:526-9. [DOI: 10.1111/ped.12279] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
52 Joosub I, Gray A, Crisostomo A, Salam A. Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia. Saudi Pharm J 2015;23:626-34. [PMID: 26702257 DOI: 10.1016/j.jsps.2015.02.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
53 Yano H, Ogawa M, Endo S, Kakuta R, Kanamori H, Inomata S, Ishibashi N, Aoyagi T, Hatta M, Gu Y, Yamada M, Tokuda K, Kunishima H, Kitagawa M, Hirakata Y, Kaku M. High frequency of IMP-6 among clinical isolates of metallo-β-lactamase-producing Escherichia coli in Japan. Antimicrob Agents Chemother 2012;56:4554-5. [PMID: 22664972 DOI: 10.1128/AAC.00617-12] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
54 Lim CL, Lee W, Lee AL, Liew LT, Nah SC, Wan CN, Chlebicki MP, Kwa AL. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH). BMC Infect Dis 2013;13:523. [PMID: 24195651 DOI: 10.1186/1471-2334-13-523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
55 Masterton RG. The new treatment paradigm and the role of carbapenems. International Journal of Antimicrobial Agents 2009;33:105.e1-8. [DOI: 10.1016/j.ijantimicag.2008.07.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
56 Rapp M, Urien S, Foissac F, Béranger A, Bouazza N, Benaboud S, Bille E, Zheng Y, Gana I, Moulin F, Lesage F, Renolleau S, Tréluyer JM, Hirt D, Oualha M. Population pharmacokinetics of meropenem in critically ill children with different renal functions. Eur J Clin Pharmacol 2020;76:61-71. [DOI: 10.1007/s00228-019-02761-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
57 Tan R, Yu A, Liu Z, Liu Z, Jiang R, Wang X, Liu J, Gao J, Wang X. Prediction of Minimal Inhibitory Concentration of Meropenem Against Klebsiella pneumoniae Using Metagenomic Data. Front Microbiol 2021;12:712886. [PMID: 34497594 DOI: 10.3389/fmicb.2021.712886] [Reference Citation Analysis]
58 Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015;15:475-85. [PMID: 25716293 DOI: 10.1016/S1473-3099(14)70950-8] [Cited by in Crossref: 121] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
59 Raza A, Sime FB, Cabot PJ, Roberts JA, Falconer JR, Kumeria T, Popat A. Liquid CO 2 Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem. ACS Biomater Sci Eng 2021;7:1836-53. [DOI: 10.1021/acsbiomaterials.0c01284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
60 Liebchen U, Rakete S, Vogeser M, Arend FM, Kinast C, Scharf C, Zoller M, Schönermarck U, Paal M. The Role of Non-Enzymatic Degradation of Meropenem-Insights from the Bottle to the Body. Antibiotics (Basel) 2021;10:715. [PMID: 34198482 DOI: 10.3390/antibiotics10060715] [Reference Citation Analysis]
61 Casals G, Hernández C, Hidalgo S, Morales B, López-Púa Y, Castro P, Fortuna V, Martínez JA, Brunet M. Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. Clin Biochem 2014;47:223-7. [PMID: 25128839 DOI: 10.1016/j.clinbiochem.2014.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
62 Tavassoli S, Gunn D, Williams OM, Darcy K. The successful treatment of a multidrug-resistant Achromobacter xylosoxidans corneal ulcer with topical meropenem. BMJ Case Rep 2018;2018:bcr-2018-225163. [PMID: 30021738 DOI: 10.1136/bcr-2018-225163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Chen C, Jin S, Zhang Z, Wei B, Wang H, Zhang K, Lv H, Dong X, Zhang X. Rhodium/Yanphos-Catalyzed Asymmetric Interrupted Intramolecular Hydroaminomethylation of trans -1,2-Disubstituted Alkenes. J Am Chem Soc 2016;138:9017-20. [DOI: 10.1021/jacs.6b03596] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
64 Rakete S, Schuster C, Paal M, Vogeser M. An isotope-dilution LC-MS/MS method for the simultaneous quantification of meropenem and its open-ring metabolite in serum. J Pharm Biomed Anal 2021;197:113944. [PMID: 33588299 DOI: 10.1016/j.jpba.2021.113944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Samuel S, Mathew BS, Veeraraghavan B, Fleming DH, Chittaranjan SB, Prakash JA. In vitro study of elution kinetics and bio-activity of meropenem-loaded acrylic bone cement. J Orthop Traumatol 2012;13:131-6. [PMID: 22461001 DOI: 10.1007/s10195-012-0191-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
66 Deghmane A, Alonso J, Taha M. Emerging drugs for acute bacterial meningitis. Expert Opinion on Emerging Drugs 2009;14:381-93. [DOI: 10.1517/14728210903120887] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chaijamorn W, Rungkitwattanakul D, Pattharachayakul S, Singhan W, Charoensareerat T, Srisawat N. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. J Crit Care 2020;60:285-9. [PMID: 32949895 DOI: 10.1016/j.jcrc.2020.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Martin-canal G, Saavedra A, Asensi J, Suarez-zarracina T, Rodriguez-guardado A, Bustillo E, Fierer J, Carton J, Collazos J, Asensi V. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses. International Journal of Antimicrobial Agents 2010;35:301-4. [DOI: 10.1016/j.ijantimicag.2009.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
69 Garnica-Velandia S, Aristizábal-Ruiz LA, Alvarez-Moreno CA. Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics (Basel) 2021;10:62. [PMID: 33440602 DOI: 10.3390/antibiotics10010062] [Reference Citation Analysis]
70 Salmon-Rousseau A, Martins C, Blot M, Buisson M, Mahy S, Chavanet P, Piroth L. Comparative review of imipenem/cilastatin versus meropenem. Med Mal Infect 2020;50:316-22. [PMID: 32035719 DOI: 10.1016/j.medmal.2020.01.001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Alvis Miranda H, Castellar-Leones SM, Elzain MA, Moscote-Salazar LR. Brain abscess: Current management. J Neurosci Rural Pract 2013;4:S67-81. [PMID: 24174804 DOI: 10.4103/0976-3147.116472] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
72 Ferrone V, Cotellese R, Cichella A, Raimondi P, Carlucci M, Palumbo P, Carlucci G. Meropenem and ciprofloxacin in complicated gastric surgery for cancer patients: A simple SPE–UHPLC–PDA method for their determination in human plasma. Biomedical Chromatography 2019;33:e4450. [DOI: 10.1002/bmc.4450] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Liebchen U, Klose M, Paal M, Vogeser M, Zoller M, Schroeder I, Schmitt L, Huisinga W, Michelet R, Zander J, Scharf C, Weinelt FA, Kloft C. Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients. Antibiotics (Basel) 2021;10:468. [PMID: 33924047 DOI: 10.3390/antibiotics10040468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Chen LR, Zhou HW, Cai JC, Zhang R, Chen GX. Combination of IMP-4 metallo-beta-lactamase production and porin deficiency causes carbapenem resistance in a Klebsiella oxytoca clinical isolate. Diagn Microbiol Infect Dis. 2009;65:163-167. [PMID: 19748427 DOI: 10.1016/j.diagmicrobio.2009.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
75 Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE. Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. Clinical Infectious Diseases 2017;65:1033-6. [DOI: 10.1093/cid/cix443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
76 Yang C, Wang J, Yin Z, Wang Q, Zhang X, Jiang Y, Shen H. A sophisticated antibiotic-loading protocol in articulating cement spacers for the treatment of prosthetic joint infection: A retrospective cohort study. Bone Joint Res 2019;8:526-34. [PMID: 31832172 DOI: 10.1302/2046-3758.811.BJR-2018-0339.R3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
77 Agrawal S, Nadel S. Acute bacterial meningitis in infants and children: epidemiology and management. Paediatr Drugs 2011;13:385-400. [PMID: 21999651 DOI: 10.2165/11593340-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
78 Chacón-González C, Rivera-Salgado D, Brenes-Chacón H, Naranjo-Zuñiga G, Ávila-Aguero ML. Use of Meropenem in a Tertiary Pediatric Hospital in Costa Rica and Its Role in the Era of Antimicrobial Stewardship. Cureus 2021;13:e15809. [PMID: 34306876 DOI: 10.7759/cureus.15809] [Reference Citation Analysis]
79 Alvarez-Uria G, Pakam R, Midde M, Naik PK. Intra-abscess administration of antibiotics through ultrasound-guided percutaneous catheter for the treatment of pyogenic liver abscess. J Clin Diagn Res 2013;7:1698-9. [PMID: 24086880 DOI: 10.7860/JCDR/2013/5685.3245] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Liu EM, Pegg KM, Oelschlaeger P. The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure. Antimicrob Agents Chemother 2012;56:6403-6. [PMID: 23006757 DOI: 10.1128/AAC.01440-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
81 Shin SH, Kim KS. Treatment of bacterial meningitis: an update. Expert Opin Pharmacother 2012;13:2189-206. [PMID: 22984938 DOI: 10.1517/14656566.2012.724399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
82 Kamp JC, Fuge J, Ringshausen FC, Grote-Koska D, Brand K, Graalmann L, Vonberg RP, Welte T, Rademacher J. Pharmacokinetics of Meropenem in People with Cystic Fibrosis-A Proof of Concept Clinical Trial. Antibiotics (Basel) 2021;10:292. [PMID: 33799542 DOI: 10.3390/antibiotics10030292] [Reference Citation Analysis]
83 Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete AG, Roberts JA, De Waele JJ. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother 2019;74:432-41. [PMID: 30376103 DOI: 10.1093/jac/dky434] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
84 Ockfen S, Egle L, Sauter K, Haber M, Becker SL, Wagenpfeil G, Graf N, Simon A. Meropenem Use in Pediatric Oncology - Audit on Indication, Appropriateness and Consumption Comparing Patient Derived and Pharmacy Dispensing Data. Klin Padiatr 2021. [PMID: 34261135 DOI: 10.1055/a-1481-8905] [Reference Citation Analysis]
85 Grigori K, Loukas YL, Malenović A, Samara V, Kalaskani A, Dimovasili E, Kalovidouri M, Dotsikas Y. Chemometrically assisted development and validation of LC–MS/MS method for the analysis of potential genotoxic impurities in meropenem active pharmaceutical ingredient. Journal of Pharmaceutical and Biomedical Analysis 2017;145:307-14. [DOI: 10.1016/j.jpba.2017.06.061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
86 Di Mauro A, Cortese F, Laforgia N, Pantaleo B, Giuliani R, Bonifazi D, Ciccone MM, Giordano P. Neonatal bacterial meningitis: a systematic review of European available data. Minerva Pediatr 2019;71:201-8. [PMID: 29160642 DOI: 10.23736/S0026-4946.17.05124-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
87 Wang XX, Ma CT, Jiang YX, Ge YJ, Liu FY, Xu WG. Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients. World J Clin Cases 2021; 9(29): 8694-8701 [PMID: 34734047 DOI: 10.12998/wjcc.v9.i29.8694] [Reference Citation Analysis]
88 Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PLoS One 2018;13:e0201667. [PMID: 30059536 DOI: 10.1371/journal.pone.0201667] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
89 Lee JH, Lee DH, Kim JS, Jung WB, Heo W, Kim YK, Kim SH, No TH, Jo KM, Ko J, Lee HY, Jun KR, Choi HS, Jang JH, Jang HJ. Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation. Front Pharmacol 2021;12:768912. [PMID: 34790131 DOI: 10.3389/fphar.2021.768912] [Reference Citation Analysis]
90 Costantinides F, Luzzati R, Tognetto D, Bazzocchi G, Biasotto M, Tirelli GC. Rapidly progressing subperiosteal orbital abscess: an unexpected complication of a group-A streptococcal pharyngitis in a healthy young patient. Head Face Med 2012;8:28. [PMID: 23067784 DOI: 10.1186/1746-160X-8-28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Chao CM, Chen CC, Huang HL, Chuang YC, Lai CC, Tang HJ. Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections. PLoS One 2016;11:e0167522. [PMID: 27907197 DOI: 10.1371/journal.pone.0167522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D. Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol 2009;41:959-66. [PMID: 19404766 DOI: 10.1007/s11255-009-9552-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
93 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-hady H. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatric Infectious Disease Journal 2017;36:358-63. [DOI: 10.1097/inf.0000000000001445] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
94 Hosmann A, Ritscher L, Burgmann H, Al Jalali V, Wulkersdorfer B, Wölfl-Duchek M, Sanz Codina M, Jäger W, Poschner S, Plöchl W, Reinprecht A, Rössler K, Gruber A, Zeitlinger M. Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels. J Antimicrob Chemother 2021:dkab286. [PMID: 34392352 DOI: 10.1093/jac/dkab286] [Reference Citation Analysis]
95 Chapelle C, Gaborit B, Dumont R, Dinh A, Vallée M. Treatment of UTIs Due to Klebsiella pneumoniae Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review. Antibiotics (Basel) 2021;10:1332. [PMID: 34827272 DOI: 10.3390/antibiotics10111332] [Reference Citation Analysis]
96 Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010;10:72. [PMID: 20298555 DOI: 10.1186/1471-2334-10-72] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
97 Chung PH, Wong KK, Tam PK. Standard management protocol to improve the short-term outcome of biliary atresia. J Paediatr Child Health 2020;56:1774-8. [PMID: 33197970 DOI: 10.1111/jpc.14698] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Kim YK, Lee DH, Jeon J, Jang HJ, Kim HK, Jin K, Lim SN, Lee SS, Park BS, Kim YW, Shin JG, Kiem S. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections. Clin Ther 2018;40:1384-95. [PMID: 30093133 DOI: 10.1016/j.clinthera.2018.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Monnet DL, Giesecke J. Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspective. J Antimicrob Chemother 2014;69:1151-3. [PMID: 24346761 DOI: 10.1093/jac/dkt478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
100 Lee DH, Kim HS, Park S, Kim HI, Lee SH, Kim YK. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation. Pharmaceutics 2021;13:1861. [PMID: 34834278 DOI: 10.3390/pharmaceutics13111861] [Reference Citation Analysis]